14036 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

After completing this program, the Roche Pharmaceutical Consultant can be expected to have a more in-depth understanding of the pharmacologic action of a variety of therapeutic agents which encompass not only Roche products but those of other pharmaceutical companies as well. In addition, he has the advantage of being actively involved in patient care in a dynamic new way.

This program has the endorsement of the University of Miami Medical School and the Department of Pharmacology and has been presented to the National Academy of Sciences/National Research Council Drug Research Board. As the program progresses, we anticipate the endorsement of the American Society for Pharmacology and Experimental Therapeutics (ASPET). You will also be reading about this program in forthcoming issues of professional journals.

At the moment, we are in the process of assessing the program. The results of our study, along with the quantifying data obtained, should provide the necessary information to permit our proceeding on a broader scale. We would appreciate any comments you might like to provide regarding the Roche Pharmaceutical Consultant Program. With your cooperation, I believe we can help meet an essential need of practicing physicians everywhere.

Very truly yours,

Roger F. Palmer, M. D.
Professor and Chairman
Department of Pharmacology
Professor of Medicine and Chief
Division of Clinical Pharmacology
Department of Medicine
University of Miami School of Medicine